To test the hypothesis that, given the role of AMP-activated protein kinase (AMPK) in regulating intracellular ATP levels, AMPK may alter ATP release from astrocytes, the main sources of extracellular ATP (eATP) within the brain.
part of the signalling pathway by which leptin inhibits food intake. 5 Conversely, orexigenic hormones, such as ghrelin, require AMPK to stimulate food intake. 6 AMPK also plays a central role in glucose homeostasis because pharmacological activation of the kinase using AICAR can augment the counter-regulatory response to insulininduced hypoglycaemia in rats. 7 To date most research on the role of AMPK in the central nervous system has focused on neurons, but glial cells, such as oligodendrocytes, microglia and astrocytes, also contain AMPK. Little is currently known, however, about its function within these cells. Astrocytes play important supporting roles for neurons, partly through releasing gliotransmitters into the extracellular space, such as ATP. 8 In the brain, enhanced extracellular ATP (eATP) levels are widely accepted as a ubiquitous stress signal, 8 for example, capable of initiating inflammatory signalling cascades by activating purinergic receptors (P2R). 9 Several pieces of data suggest a potential role for glial-derived eATP in the regulation of whole-body energy/glucose homeostasis that could be modulated by glial AMPK.
Firstly, obesity is associated with glial cell activation in mice [10] [11] [12] and humans 13 and recent data suggest that glia play a role in regulating feeding behaviour. [14] [15] [16] [17] Astrocyte-derived eATP is broken down within the extracellular space to adenosine, which, via activation of the adenosine A1 receptor, inhibits the activity of hypothalamic agouti-related protein (AgRP) neurons, which are critical for the regulation of food intake. 18 This provides evidence for ATP acting as a gliotransmitter to modulate energy homeostasis. Moreover, microglia can be activated by eATP, leading to initiation of the NF-κB signalling cascade and production of proinflammatory cytokines, 9 with NF-κB signalling in neurons and glia playing an important role in the regulation of energy homeostasis. 14, 19 Proinflammatory cytokine signalling is directly involved in the central control of energy homeostasis because intracerebroventricular injection of tumour necrosis factor-α acutely inhibits food intake in rats. 20 eATP is also neuromodulatory via activation of Ca
2+
-permeable P2X receptors and has been shown to excite hypothalamic steroidogenic factor 1 (SF-1)
neurons, which are involved in the regulation of food intake. 21 Given the importance of eATP in regulating myriad processes within the brain and the role of AMPK in regulating intracellular ATP levels, we hypothesized that AMPK may regulate eATP levels by blocking or reducing ATP release from astrocytes, thus maintaining intracellular ATP for metabolism. We tested this hypothesis in vitro by examining ATP release from human U373 astrocytoma cells and mouse primary hypothalamic (HTAS) and cortical astrocytes (CRTAS) using the structurally distinct activators of AMPK, A-769662, AICAR and metformin. We conclude that only A-769662 alters eATP levels, which is mediated by increased release of calcium from intracellular stores, in a cell autonomous manner.
| MATERIALS AND METHODS

| Chemicals
A-769662, AICAR and metformin were purchased from Tocris (Bristol, UK). A-769662 was dissolved in DMSO (applied at a maximum volume:volume ratio of 0.1%). AICAR and metformin were dissolved in water.
| Cell culture
U373 cells were purchased from Public Health England. Primary mouse astrocytes were isolated from neonatal mice P1-5 and validated as astrocyte-enriched cultures of >80% GFAP-positive cells. Cultures contained <2% Iba1-positive microglial cells ( Figure S1 ). Wild-type (WT) and AMPKα1/α2 null mouse embryonic fibroblast (MEF) cells were a gift from Dr Benoit Viollet. All cell cultures were grown in stock media (DMEM;
Sigma, UK) supplemented with 10% Hyclone FBS (ThermoFisher, UK) containing 25 mM glucose. Cells were seeded the day before experimentation and grown in media containing 7.5 mM glucose (sufficient to prevent glucose depletion overnight), supplemented with 10% FBS, with the exception of MEF cells, which were maintained in 25 mM glucose-containing media. On the day of experimentation, cells were cultured in serum-free media (Gibco, UK) containing 2.5 mM glucose, a physiologically relevant brain glucose concentration, for 2 hours before treatment (up to 3 hours).
| Immunoblotting
Cells were grown to 60% to 70% confluence in 60-mm dishes. Protein was isolated using lysis buffer, protein concentrations determined by the Bradford method, and lysates subjected to SDS-PAGE and electrotransferred to nitrocellulose membrane. Proteins (total and phosphorylated)
were immunoblotted and identified with infrared fluorescence using the Licor Odyssey scanner (see File S1, supplementary methods for antibody details).
| Determination of ATP concentrations
Extracellular and intracellular ATP levels were determined using ATPLite 2-step (PerkinElmer, UK) as per the manufacturer's instructions, with minor modifications (File S1, supplementary methods).
| Calcium imaging
Intracellular calcium was measured using either Fluo4 Direct (ThermoFisher, UK) using a Pherastar FS plate reader or Fura-2 (Life Technologies, UK) for single-cell calcium imaging (File S1, supplementary methods).
| Assessment of cellular metabolism
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of U373, AMPK WT and AMPK alpha1/alpha2 MEF cells was assessed using a Seahorse Bioscience XFe96 extracellular flux analyser (see File S1, supplementary methods for assay conditions).
| Statistical analysis
A 1-sample t-test was used to determine significant changes in phos- We therefore performed single-cell ratiometric calcium imaging using 
| Chelation of intracellular calcium with BAPTA-AM attenuates A-769662-induced increases in eATP
To determine whether the change in intracellular calcium was directly responsible for the increased release of ATP from astrocytes, we che-
] i using BAPTA-AM (50 μM; 30 minutes pre-incubation).
There was a non-significant trend for reduced A-769662 response in 
| A-769662 increases eATP levels in several endocrine cell types
To examine whether the ability of high concentrations of A-769662 to alter ATP release is a general phenomenon across cell types, we 
| A-769662 reduces ECAR in an AMPKdependent and AMPK-independent manner
It is known that AMPK opposes the Warburg effect, 24 . E, Treatment of primary CRTAS (n = 9) with increasing concentrations of A-769662 for 30 minutes also increased eATP levels, with representative immunoblots depicted in (F). *P < .05;** P < .01; ***P < .001
null MEFs, although the magnitude of the response was reduced.
Oxygen consumption rate was not significantly altered in any cell type ( Figure 5B ,E,H). These data indicate that the reduction in ECAR induced by A-769662 has AMPK-dependent and AMPK-independent components.
| DISCUSSION
Astrocytes are the main source of eATP within the brain 25 and, given that AMPK acts to maintain intracellular ATP levels, we hypothesized that AMPK regulates ATP release from astrocytes. We postulated that activation of AMPK would limit ATP release, thus maintaining the pool of ATP available for metabolism. In contrast, we found that rats. 30 In muscle, eATP can enhance glucose uptake in a P2Y
receptor-dependent mechanism, that induces GLUT4 translocation to the membrane. 31 Chronically elevated levels of ATP have been reported to induce insulin resistance in cultured adipocytes, 32 and, in blood, eATP can enhance the release of mature IL-1β from macrophages, via a P2X7 receptor-dependent mechanism. 33 ATP can be broken down in the extracellular space to form adenosine and recent evidence suggests that astrocyte-derived adenosine (released as ATP)
can reduce food intake via activation of AgRP neuron adenosine A1
receptors. 18 Adenosine can also increase glucose uptake in mouse neurons and astrocytes via activation of the adenosine 2B receptor. 34 In conclusion, our data do not support a role for AMPK in acutely regulating ATP release from astrocytes. Instead, we find that complete loss of AMPK activity, mediated by knockout of both catalytic subunits, reduced eATP levels by reducing intracellular ATP levels. A-769662 increased eATP levels from mouse glucosensing hypothalamic GT1-7 neurons (A; n = 5), human Sh-SY5Y neuroblastoma cells (B; n = 6), murine BV-2 microglia (C; n = 7), rat hepatoma H4IIE cells (D; n = 6), mouse C2C12 myoblasts (E; n = 9) and rat pancreatic β-cell INS-1E cells (F; n = 4). *P < .05; **P < .01;***P< .001
